Y-mAbs Therapeutics Inc.

750 Third Avenue, 9th Floor
New York
New York
10017
United States

Tel: 212-847-9841

About Y-mAbs Therapeutics Inc.

YmAbs is a clinical stage biopharmaceutical company focused on developing new cancer treatments through immunotherapies. In addition, YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies targeting GD2 and B7-H3. To further improve our bispecific antibodies, we are collaborating with MSK on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. Our treatments could potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA licensure. Each candidate has the potential to treat a variety of high-risk cancers.
YEAR FOUNDED:
April 2014
LEADERSHIP:
Founder, President and Head of Business Development and Strategy: Thomas Gad
CEO: Claus Moller
CFO: Bo Kruse
SVP, Head of Technical Operations: Torben Lund-Hansen, PhD
SVP, CMO: Ole Baadsgaard, MD, DMSc
CAREER:
Please click here for YmAbs' job opportunities.

131 articles about Y-mAbs Therapeutics Inc.

Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

11/7/2022

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter of 2022.
Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022

11/2/2022

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that ended September 30, 2022, on Monday, November 7, 2022, after the close of the U.S. financial markets.
FDA's ODAC Unanimously Votes against Y-mAbs' Pediatric Neuroblastoma Treatment

10/28/2022

The FDA's Oncologic Drugs Advisory Committee voted unanimously against approving l-omburtamab for children with a rare form of neuroblastoma, citing complex review issues.
Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab

10/28/2022

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced the outcome of the meeting of the U.S. Food and Drug Administration (“FDA”) Oncologic Drugs Advisory Committee (“ODAC”), which reviewed investigational 131I-omburtamab (“omburtamab”) for the treatment of CNS/leptomeningeal metastasis from neuroblastoma.
Y-mAbs Announces Pivotal Data for Omburtamab

10/3/2022

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced clinical data on the Company’s product candidate OMBLASTYS® (131I-omburtamab) for the treatment of CNS/leptomeningeal metastasis from neuroblastoma.
Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil

9/26/2022

Y-mAbs Therapeutics, Inc. today announced that Adium Pharma S.A. (“Adium”) has submitted a regulatory filing for DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma.
Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab

9/1/2022

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), today announced that a meeting of the Oncologic Drugs Advisory Committee (“ODAC”) of the U.S. Food and Drug Administration (“FDA”) has been scheduled for October 28, 2022 to review the Company’s Biological License Application (“BLA”) for its product candidate, OMBLASTYS® (omburtamab), an investigational radiolabeled antibody construct.
Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma

8/30/2022

Y-mAbs Therapeutics, Inc. and Takeda Israel, announced today that the Israeli Ministry of Health has approved DANYELZA in Israel for the treatment, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
Y-mAbs Announces Second Quarter 2022 Financial Results and Recent Corporate Developments

8/8/2022

Y-mAbs Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported financial results for the second quarter of 2022.
Y-mAbs to Announce Second Quarter 2022 Financial and Operating Results on August 8, 2022

8/2/2022

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that ended June 30, 2022, on Monday, August 8, 2022, after the close of the U.S. financial markets.
ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177

7/21/2022

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced the signing of a clinical supply agreement for its medical radioisotope no-carrier-added lutetium-177 with Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.
Y-mAbs’ Announces Clearance of IND for GD2-SADA

7/12/2022

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced initiation of its first clinical trial with a SADA construct.
Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS® (omburtamab) for the Treatment of Neuroblastoma for Priority Review

5/31/2022

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that the Biologics License Application (“BLA”) for OMBLASTYS® (omburtamab) for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma has been accepted for priority review by the U.S. Food and Drug Administration (“FDA”).
Takeda, Seagen and Y-mAbs Highlight Data in Difficult Cancers Ahead of ASCO

5/27/2022

Two therapies for different cancers are moving forward in development following positive outcomes in their clinical trials ahead of the ASCO's annual meeting in early June 2022.
Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint

5/26/2022

Y-mAbs Therapeutics, Inc. announced that Dr. Shakeel Modak, MD from Memorial Sloan Kettering will present results from the naxitamab-based chemoimmunotherapy trial in patients with chemoresistant high-risk neuroblastoma, at the American Society of Clinical Oncology Annual Meeting to be held June 3-7, 2022.
Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022

5/3/2022

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter March 31, 2022 on Monday, May 9, 2022, after the close of the U.S. financial markets.
Y-mAbs Announces Executive Management Changes and Provides 2022 Revenue Guidance and Financial Update

4/27/2022

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the following executive management changes: Dr. Claus Moller has stepped down from his positions as Chief Executive Officer and Board Member effective immediately.
Y-mAbs Announces Presentation of SADA Technology at AACR

4/8/2022

Y-mAbs Therapeutics, Inc. announced that a poster presentation featuring preclinical data from its GD2 SADA construct will be presented at the AACR Annual Meeting 2022, which takes place in New Orleans, Louisiana from April 8-13, 2022.
Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA

4/1/2022

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that on March 31, 2022, the Company completed the resubmission of its Biologics License Application (“BLA”) for 131 I-omburtamab (“omburtamab”) to the FDA.
Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Developments

2/24/2022

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), today reported financial results for the fourth quarter and the full year ended December 31, 2021 and provided recent corporate highlights.